Introduction: We present the final analysis of the phase 3, double-blind, placebo-controlled CLL12 trial evaluating ibrutinib in patients with early stage CLL at increased risk of progression defined by a comprehensive score (NCT02863718). Methods: We randomly assigned patients with asymptomatic, treatment-naïve Binet stage A CLL at increased risk of progression in a 1:1 ratio to receive ibrutinib (n = 182) or placebo (n = 181) at a dose of 420 mg daily.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with P.
Contact P., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack